Risk factors
Pacific Biosciences of California (PACB) risk factors
Item 1A of every Pacific Biosciences of California, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors67 risks6 new2 dropped5 reworded
Pacific Biosciences completed the disposition of its short-read DNA sequencing assets on January 30, 2026, while retaining certain liabilities.
Filed Feb 25, 2026 - FY2024 10-K risk factors63 risks
Pacific Biosciences faces ongoing net losses, negative cash flow, and debt burdens requiring cost reduction initiatives. The business relies on complex manufacturing of sequencing systems like Revio and Onso, facing intense competition and geopolitical risks in China and Taiwan. Patent litigation and complex intellectual property challenges significantly threaten the company's competitive advantage.
Filed Mar 17, 2025